Combinaison << inhibiteur des SGLT2-agoniste des recepteurs du GLP-1 >> pour traiter le diabete de type 2.

[en] Some sodium-glucose cotransporter type 2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) have proven their ability to reduce major cardiovascular events in patients with type 2 diabetes at high cardiovascular risk. Furthermore, SGLT2is reduce the risk of hospitalization for heart failure and the progression of renal disease. The 2018 ADA-EASD consensus gave the preference to either SGLT2is or GLP-1 RAs to prevent these complications. Underlying protective mechanisms are complex, differ between the two pharmacological classes and are potentially complementary, thus providing a rationale for a combination in patients at very high risk. Some studies already showed positive complementary effects on glucose control, body weight and arterial blood pressure, but not on cardiovascular and/or renal outcomes yet.

Disciplines :

Pharmacy, pharmacology & toxicology

Author, co-author :

Scheen, André ; Université de Liège - ULiège > Département des sciences cliniques > Département des sciences cliniques

Language :

French

Title :

Combinaison << inhibiteur des SGLT2-agoniste des recepteurs du GLP-1 >> pour traiter le diabete de type 2.

Alternative titles :

[en] Combination therapy with SGLT2 inhibitor and GLP-1 receptor agonist in type 2 diabetes

Publication date :

2019

Journal title :

Revue Médicale Suisse

ISSN :

1660-9379

Publisher :

Medecine et Hygiène, Switzerland

Volume :

Issue :

659

Pages :

1436-1441

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 05 September 2019

Statistics

Number of views

320 (4 by ULiège)

Number of downloads

432 (3 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

Bibliography

Cefalu WT, Kaul S, Gerstein HC, et al. Cardiovascular outcomes trials in type 2 diabetes: where do we go from here? Reflections from a Diabetes Care Editors' Expert Forum. Diabetes Care 2018;41:14-31.
Ahmed HM, Khraishah H, Cho L. Cardioprotective anti-hyperglycaemic medications: a review of clinical trials. Eur Heart J 2018;39:2368-75.
Scheen AJ, Paquot N. Inhibiteur des SGLT2 ou analogue du GLP-1 chez un patient diabetique avec maladie cardiovasculaire? Rev Med Suisse 2018;14:1460-5.
Busch RS, Kane MP. Combination SGLT2 inhibitor and GLP-1 receptor agonist therapy: a complementary approach to the treatment of type 2 diabetes. Postgrad Med 2017;129:686-97.
DeFronzo RA. Combination therapy with GLP-1 receptor agonist and SGLT2 inhibitor. Diabetes Obes Metab 2017;19:1353-62.
De Block C. SGLT2 inhibitors and GLP-1 receptor agonists: a sound combination. Lancet Diabetes Endocrinol 2018;6:349-52.
Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2019;380:347-57.
Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 2019;380:2295-306.
Hernandez AF, Green JB, Janmohamed S, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet 2018;392:1519-29.
Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet 2019; Published online June 10, 2019.
Davies MJ, D'Alessio DA, Fradkin J, et al. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2018;61:2461-98.
Pfeifer M, Townsend RR, Davies MJ, et al. Effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on blood pressure and markers of arterial stiffness in patients with type 2 diabetes mellitus: a post hoc analysis. Cardiovasc Diabetol 2017;16:29.
Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373:2117-28.
Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017;377:644-57.
Scheen AJ, Ernest P, Jandrain B. Protection cardio-rénale par les inhibiteurs des SGLT2 (gliflozines): d'EMPA-REG OUTCOME à CANVAS. Rev Med Suisse 2017;13:1421-6.
Scheen AJ. Focus sur l'empagliflozine: synthèse des analyses post-hoc de l'étude cardiovasculaire EMPA-REG OUTCOME. Rev Med Liege 2019;74:185-91.
Zelniker TA, Wiviott SD, Raz I, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet 2019;393:31-9.
Scheen AJ. Etudes cardiovasculaires chez le patient diabétique de type 2 à risque: conclusions et impact des essais publiés en 2017-2018. Médecine des maladies Métaboliques 2019;13:10-23.
van Baar MJB, van Ruiten CC, Muskiet MHA, et al. SGLT2 inhibitors in combination therapy: from mechanisms to clinical considerations in type 2 diabetes management. Diabetes Care 2018;41:1543-56.
Scheen AJ, Paquot N. Combinaison gliptine-gliflozine dans le traitement du diabète de type 2. Rev Med Suisse 2016;12:1384-8.
Scheen AJ, Paquot N. Options thérapeutiques chez un patient diabétique de type 2 mal contrôlé par une insuline basale. Rev Med Suisse 2017;13:1416-20.
Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016;375:311-22.
Scheen AJ, Wallemacq C, Jandrain B, et al. Protection cardiovasculaire du patient diabétique de type 2: d'EMPAREG OUTCOME à LEADER. Rev Med Suisse 2016;12:1370-5.
Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2016;375:1834-44.
Holman RR, Bethel MA, Mentz RJ, et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2017;377:1228-39.
Bethel MA, Patel RA, Merrill P, et al. Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis. Lancet Diabetes Endocrinol 2018;6:105-13.
Scheen AJ. GLP-1 receptor agonists and cardiovascular protection. Class effect or not? Diabetes Metab 2018;44:193-6.
Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial. Lancet, Published online June 10, 2019.
Scheen AJ. Effects of glucose-lowering agents on renal surrogate endpoints and hard clinical outcomes in patients with type 2 diabetes. Diabetes Metab 2019;45:110-21.
Scheen AJ. Cardiovascular outcome studies in type 2 diabetes: Comparison between SGLT2 inhibitors and GLP-1 receptor agonists. Diabetes Res Clin Pract 2018;143:88-100.
Consoli A, Formoso G, Baldassarre MPA, et al. A comparative safety review between GLP-1 receptor agonists and SGLT2 inhibitors for diabetes treatment. Expert Opin Drug Saf 2018;1-10.
Scheen AJ. Diabetes Research & Clinical Practice Series: Implications of the recent CVOTs in Type 2 Diabetes: Impact on guidelines: the endocrinologist point of view. Diabetes Res Clin Pract 2019; epub ahead of print.
Goncalves E, Bell DSH. Combination treatment of SGLT2 inhibitors and GLP-1 receptor agonists: symbiotic effects on metabolism and cardiorenal risk. Diabetes Ther 2018;9:919-26.
Doumas M, Imprialos K, Stavropoulos K, et al. Combination of SGLT-2 inhibitors and GLP-1 receptor agonists: potential benefits in surrogate and hard endpoints. Curr Pharm Des 2018;24:1879-86.
Martinez R, Al-Jobori H, Ali AM, et al. Endogenous glucose production and hormonal changes in response to canagliflozin and liraglutide combination therapy. Diabetes 2018;67:1182-9.
Ahn CH, Oh TJ, Kwak SH, et al. Sodium-glucose cotransporter-2 inhibition improves incretin sensitivity of pancreatic beta-cells in people with type 2 diabetes. Diabetes Obes Metab 2018;20:370-7.
Pereira MJ, Lundkvist P, Kamble PG, et al. A randomized controlled trial of dapagliflozin plus once-weekly exenatide versus placebo in individuals with obesity and without diabetes: metabolic effects and markers associated with bodyweight loss. Diabetes Ther 2018;9:1511-32.
Frias JP, Guja C, Hardy E, et al. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabetes Endocrinol 2016;4:1004-16.
Ludvik B, Frias JP, Tinahones FJ, et al. Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebocontrolled trial. Lancet Diabetes Endocrinol 2018;6:370-81.
Fulcher G, Matthews DR, Perkovic V, et al. Efficacy and safety of canagliflozin when used in conjunction with incretin-mimetic therapy in patients with type 2 diabetes. Diabetes Obes Metab 2016;18:82-91.
Terauchi Y, Utsunomiya K, Yasui A, et al. Safety and efficacy of empagliflozin as add-on therapy to GLP-1 receptor agonist (liraglutide) in Japanese patients with type 2 diabetes mellitus: a randomised, double-blind, parallel-group phase 4 study. Diabetes Ther 2019;10:951-63.
Frias JP, Hardy E, Ahmed A, et al. Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly, or dapagliflozin added to metformin monotherapy in subgroups of patients with type 2 diabetes in the DURATION-8 randomized controlled trial. Diabetes Obes Metab 2018;20:1520-5.
Jabbour SA, Frias JP, Guja C, et al. Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly, or dapagliflozin, added to metformin monotherapy, on body weight, systolic blood pressure, and triglycerides in patients with type 2 diabetes in the DURATION-8 study. Diabetes Obes Metab 2018;20:1515-9.
Carretero Gomez J, Arevalo Lorido JC, Gomez Huelgas R, et al. Combination therapy with glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors in older patients with type 2 diabetes: a real-world evidence study. Can J Diabetes 2018;43:186-92.
Harashima SI, Inagaki N, Kondo K, et al. Efficacy and safety of canagliflozin as add-on therapy to a glucagon-like peptide-1 receptor agonist in Japanese patients with type 2 diabetes mellitus: A 52-week, open-label, phase IV study. Diabetes Obes Metab 2018;20:1770-5.
Arevalo-Lorido JC, Gomez JC, Huelgas RG, et al. Lowering blood pressure with the combination of a sodium-glucose cotransporter 2 inhibitor and a glucagonlike peptide-1 receptor agonist in type 2 diabetic patients: a clinical evidence. High Blood Press Cardiovasc Prev 2018;25:417-20.